Floatz logo

PANITUMUMAB

Oncology

Astellas Pharma Incmonoclonal_antibodyPhase 2Active
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

927 Active assets in the Oncology cohort.

Asset / SponsorPhaseRating
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
LIDOCAINE
Medical College of Wisconsin
Phase 4BB
Relatlimab
Bristol-Myers Squibb
Phase 2BB
DINITROGEN MONOXIDE
Medical College of Wisconsin
Phase 4BB
Bxcl501
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

PANITUMUMAB is also rated in:

colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →